Literature DB >> 33371679

Sialyltransferase Inhibitors Suppress Breast Cancer Metastasis.

Chih-Wei Fu1,2, Han-En Tsai1, Wei-Sheng Chen1,2, Tzu-Ting Chang1, Chia-Ling Chen1, Pei-Wen Hsiao3, Wen-Shan Li1,4,5,6,7.   

Abstract

We report the synthesis and evaluation of a series of cell-permeable and N- versus O-selective sialyltransferase inhibitors. Inhibitor design entailed the functionalization of lithocholic acid at C(3) and at the cyclopentane ring side chain. Among the series, FCW34 and FCW66 were shown to inhibit MDA-MB-231 cell migration as effectively as ST3GALIII-gene knockdown did. FCW34 was shown to inhibit tumor growth, reduce angiogenesis, and delay cancer cell metastasis in animal models. Furthermore, FCW34 inhibited vessel development and suppressed angiogenic activity in transgenic zebrafish models. Our results provide clear evidence that FCW34-induced sialyltransferase inhibition reduces cancer cell metastasis by decreasing N-glycan sialylation, thus altering the regulation of talin/integrin/FAK/paxillin and integrin/NFκB signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33371679     DOI: 10.1021/acs.jmedchem.0c01477

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Synthesis and biological evaluation of selective phosphonate-bearing 1,2,3-triazole-linked sialyltransferase inhibitors.

Authors:  Christopher Dobie; Andrew P Montgomery; Rémi Szabo; Haibo Yu; Danielle Skropeta
Journal:  RSC Med Chem       Date:  2021-06-29

Review 2.  Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention?

Authors:  Silvia Pietrobono; Barbara Stecca
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

3.  p-Coumaric acid, Kaempferol, Astragalin and Tiliroside Influence the Expression of Glycoforms in AGS Gastric Cancer Cells.

Authors:  Iwona Radziejewska; Katarzyna Supruniuk; Michał Tomczyk; Wiktoria Izdebska; Małgorzata Borzym-Kluczyk; Anna Bielawska; Krzysztof Bielawski; Anna Galicka
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.